Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.11B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 3.21%
Avg Daily Range (30 D):	$0.16 | 4.60%
Avg Daily Range (90 D):	$0.12 | 4.25%

Institutional Daily Volume
Avg Daily Volume:	4.06M
Avg Daily Volume (30 D):	15.43M
Avg Daily Volume (90 D):	14.14M

Trade Size
Avg Trade Size (Sh.):	185
Avg Trade Size (Sh.) (30 D):	355
Avg Trade Size (Sh.) (90 D):	414

Institutional Trades
Total Institutional Trades:	5,458
Avg Institutional Trade:	$2.53M
Avg Institutional Trade (30 D):	$1.85M
Avg Institutional Trade (90 D):	$1.9M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.88M
Avg Closing Trade (30 D):	$2.65M
Avg Closing Trade (90 D):	$2.17M
Avg Closing Volume:	388.04K

News

Mar 5, 2026 @ 10:27 PM Iovance Biotherapeutics: The High‑Risk Canc... Source: Prosper Junior Bakiny

Feb 23, 2026 @ 8:15 AM 1 Nearly Unknown Biotech Stock Set To Go Parabolic... Source: Adria Cimino

Feb 20, 2026 @ 10:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Feb 18, 2026 @ 10:17 PM Stock Market Today, Feb. 18: ImmunityBio Soars Aft... Source: Josh Kohn-Lindquist

Feb 5, 2026 @ 10:15 PM Best-in-Class Real-World Data Support Early Amtagv... Source: Na

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.25	$-.33	$-.36
Diluted EPS		$-.33	$-.36
Revenue	$67.46M	$59.95M	$49.32M
Gross Profit	$28.98M	$3.29M	$-.42M
Net Income / Loss	$-91.25M	$-111.66M	$-116.16M
Operating Income / Loss	$-94.9M	$-113.77M	$-121.22M
Cost of Revenue	$38.48M	$56.66M	$49.74M
Net Cash Flow	$25.69M	$-39.64M	$56M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1